ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
“Challenges which others have deemed unsolvable are the problems we are solving.”
~ Jeffrey S. Aronin
Paragon founder, chairman and CEO
Portfolio
Since 2017, Paragon has successfully launched seven portfolio companies, including a recent upsized IPO, while maintaining a consistent flow of companies in development.
Leveraging its proprietary fibroblast technology platform to expand an innovative gene therapy pipeline, developing personalized treatments for underserved disorders, including epidermolysis bullosa and localized scleroderma.
Concentrating on cell therapy treatments for serious diseases with high, unmet needs with an initial focus on the eye, including geographic atrophy age-related macular degeneration and advanced retinitis pigmentosa.
Creating treatments for central nervous system movement disorders and fluency disorders, including Tourette syndrome and childhood-onset fluency disorder (stuttering) in adults.
Evozyne is combining the exquisite complexity of nature with advanced machine learning to create novel proteins with extraordinary impact across a variety of industries.
Commercializing biopharmaceutical treatment options for people living with rare diseases, including disorders of sleep and wakefulness, such as narcolepsy, Prader-Willi syndrome and myotonic dystrophy.
Assisting radiologists to significantly improve clinical assessment and characterization of cancerous breast abnormalities through artificial intelligence-driven technology that enhances clinical insights.
News
Sai Chavala, M.D., Receives ARVO Foundation Ludwig Von Sallmann Clinician-Scientist Award
Dr. Chavala is co-founder of CiRC Biosciences with Jeff Aronin, chairman and CEO of Paragon Biosciences Chicago, June 3, 2021—CiRC Biosciences, Inc., Co-Founder and Chief Scientific Officer Sai Chavala, M.D., has been [...]
Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials
Funding led by Paragon Biosciences, joined by Fidelity Management & Research Company LLC and Valor Equity Partners Chicago, March 23, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company founded to develop [...]
CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP)
Cell Therapy Platform Seeks to Restore Vision for People with RP Chicago, March 10, 2021— CiRC Biosciences, Inc., a privately held cell therapy company, today announced that the U.S. Food and Drug [...]
Sai Chavala, M.D., Receives ARVO Foundation Ludwig Von Sallmann Clinician-Scientist Award
Dr. Chavala is co-founder of CiRC Biosciences with Jeff Aronin, chairman and CEO of Paragon Biosciences Chicago, June 3, 2021—CiRC Biosciences, Inc., Co-Founder and [...]
Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials
Funding led by Paragon Biosciences, joined by Fidelity Management & Research Company LLC and Valor Equity Partners Chicago, March 23, 2021 – Emalex Biosciences, [...]
CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP)
Cell Therapy Platform Seeks to Restore Vision for People with RP Chicago, March 10, 2021— CiRC Biosciences, Inc., a privately held cell therapy company, [...]
Sai Chavala, M.D., Receives ARVO Foundation Ludwig Von Sallmann Clinician-Scientist Award
Dr. Chavala is co-founder of CiRC Biosciences with Jeff Aronin, chairman and CEO of Paragon Biosciences Chicago, June 3, 2021—CiRC Biosciences, Inc., Co-Founder and [...]
Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials
Funding led by Paragon Biosciences, joined by Fidelity Management & Research Company LLC and Valor Equity Partners Chicago, March 23, 2021 – Emalex Biosciences, [...]
CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP)
Cell Therapy Platform Seeks to Restore Vision for People with RP Chicago, March 10, 2021— CiRC Biosciences, Inc., a privately held cell therapy company, [...]
